Dietary fatty acids and brain mechanism of action throughout the lifespan

Neurology Psychiatry and Brain Research

Volumn 11, Issue 3, 2004, Pages 149-160

  Luzon Toro, Berta ^a,b   Schaefer, Stephanie ^a   Wirths, Oliver ^a   Jiménez López, Jesús ^b   Boza Puerta, Julio ^b   Geerlings, Arjan ^b   Falkai, Peter ^a   Bayer, Thomas A ^a,c  

^a SAARLAND UNIVERSITY   (Germany)

^b Puleva Biotech SA   (Spain)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Arachidonic acid; Brain; Cognition; Docosahexaenoic acid; Infant; Polyunsaturated fatty acids; Schizophrenia

Indexed keywords

5,8,11,14,17 ICOSAPENTAENOIC ACID; ARACHIDONIC ACID; CERVONIC ACID; FATTY ACID; NEUROTRANSMITTER; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID;

AGING; ALZHEIMER DISEASE; BRAIN DEVELOPMENT; BRAIN FUNCTION; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; EXCITABLE MEMBRANE; FAT INTAKE; LIFESPAN; NERVE CELL DIFFERENTIATION; NEUROPATHOLOGY; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 11044226702     PISSN: 09419500     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (191)

1. Adams P B, Lawson S, Sanigorski A, Sinclair A J (1996) Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31: S157-61.
2. Agostoni C, Trojan S, Bellu R, Riva E, Giovannini M (1995) Neurodevelopmental quotient of healthy term infants at 4 months and feeding practice: the role of long-chain polyunsaturated fatty acids. Pediatr Res 38: 262-6.
3. Alessandri J M, Poumes-Ballihaut C, Langelier B, Perruchot M H, Raguenez G, Lavialle M, Guesnet P (2003) Incorporation of docosahexaenoic acid into nerve membrane phospholipids: bridging the gap between animals and cultured cells. Am J Clin Nutr 78: 702-10.
4. Amate L, Gil A, Ramirez M (2001) Dietary long-chain polyunsaturated fatty acids from different sources affect fat and fatty acid excretions in rats. J Nutr 131: 3216-21.
5. Arnold S E, Trojanowski J Q (1996) Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathol (Berl) 92: 217-31.
6. Assies J (2001) Significantly Reduced Docosahexaenoic and Docosapentaenoic Acid Concentrations in Erythrocyte Membranes from Schizophrenic Patients Compared with a Carefully Matched Control Group. Soc Biol Psych 49: 510-522.
7. Auestad N, Halter R, Hall R T, Blatter M, Bogle M L, Burks W, Erickson J R, Fitzgerald K M, Dobson V, Innis S M, Singer L T, Montalto M B, Jacobs J R, Qiu W, Bornstein M H (2001) Growth and development in term infants fed long-chain polyunsaturated fatty acids: a double-masked, randomized, parallel, prospective, multivariate study. Pediatrics 108: 372-81.
8. Auestad N, Montalto M B, Hall R T, Fitzgerald K M, Wheeler R E, Connor W E, Neuringer M, Connor S L, Taylor J A, Hartmann E E (1997) Visual acuity, erythrocyte fatty acid composition, and growth in term infants fed formulas with long chain polyunsaturated fatty acids for one year. Ross Pediatric Lipid Study. Pediatr Res 41: 1-10.
9. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues J F, Renaud S (2002) Fish, meat, and risk of dementia: cohort study. Bmj 325: 932-3.
10. Barcelo-Coblijn G, Hogyes E, Kitajka K, Puskas L G, Zvara A, Hackler L, Jr., Nyakas C, Penke Z, Farkas T (2003) Modification by docosahexaenoic acid of age-induced alterations in gene expression and molecular composition of rat brain phospholipids. Proc Natl Acad Sci U S A 100: 11321-6. Epub 2003 Sep 17.
11. Bayer T A, Wirths O, Majtenyi K, Hartmann T, Multhaup G, Beyreuther K, Czech C (2001) Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 11: 1-11.
12. Birch E E, Birch D G, Hoffman D R,Uauy R (1992) Dietary essential fatty acid supply and visual acuity development. Invest Ophthalmol Vis Sci 33: 3242-53.
13. Birch E E, Garfield S, Hoffman D R, Uauy R,Birch D G (2000) A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol 42: 174-81.
14. Birch E E, Hoffman D R, Uauy R, Birch D G,Prestidge C (1998) Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants. Pediatr Res 44: 201-9.
15. Blok W L, Katan M B,van der Meer J W (1996) Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. J Nutr 126: 1515-33.
16. Boehm G, Borte M, Bohles H J, Muller H, Kohn G,Moro G (1996) Docosahexaenoic and arachidonic acid content of serum and red blood cell membrane phospholipids of preterm infants fed breast milk, standard formula or formula supplemented with n-3 and n-6 long-chain polyunsaturated fatty acids. Eur J Pediatr 155: 410-6.
17. Bourre J M (1992) Structural and functional importance of dietary polyunsaturated fatty acids in the nervous system. Adv Exp Med Biol 318: 211-229.
18. Bourre J M, Francois M, Youyou A, Dumont O, Piciotti M, Pascal G,Durand G (1989) The effects of dietary alpha-linolenic acid on the composition of nerve membranes, enzymatic activity, amplitude of electrophysiological parameters, resistance to poisons and performance of learning tasks in rats. J Nutr 119: 1880-92.
19. Burr G O,Burr M M (1973) Nutrition classics from The Journal of Biological Chemistry 82:345-67, 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. Nutr Rev 31: 248-9.
20. Burr G O,Burr M M (1973) Nutrition classics from The Journal of Biological Chemistry 82:345-67, 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. Nutr Rev 31: 248-9.
21. Carlson S E, Ford A J, Werkman S H, Peeples J M,Koo W W (1996) Visual acuity and fatty acid status of term infants fed human milk and formulas with and without docosahexaenoate and arachidonate from egg yolk lecithin. Pediatr Res 39: 882-8.
22. Carlson S E, Werkman S H, Rhodes P G,Tolley E A (1993) Visual-acuity development in healthy preterm infants: effect of marine-oil supplementation. Am J Clin Nutr 58: 35-42.
23. Carnielli V P, Wattimena D J, Luijendijk I H, Boerlage A, Degenhart H J, Sauer P J (1996) The very low birth weight premature infant is capable of synthesizing arachidonic and docosahexaenoic acids from linoleic and linolenic acids. Pediatr Res 40: 169-74.
24. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Leguisquet A M, Besnard J C, Durand G (1998) Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr 128: 2512-9.
25. Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G (2001) Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids 36: 937-44.
26. Champeil-Potokar G, Denis I, Goustard-Langelier B, Alessandri J M, Guesnet P, Lavialle M (2004) Astrocytes in culture require docosahexaenoic acid to restore the n-3/n-6 polyunsaturated fatty acid balance in their membrane phospholipids. J Neurosci Res 75: 96-106.
27. Chaves-Carballo E (2003) [Diet therapy in the treatment of neuropediatric disorders]. Rev Neurol 37: 267-74.
28. Christen Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71: 621S-629S.
29. Clandinin M T, Fatty acid metabolism in relation to development, membrane structure, and signaling., in Handbook of Essential Fatty Acid Biology: Biochemistry, Physiology, and Behavioral Neurobiology., M.D. Yehuda S, eds., Editor. 1997, Humana Press: Totowa, NJ. p. 15-66.
30. Clandinin M T, Chappell J E, Heim T, Swyer P R, Chance G W (1981) Fatty acid accretion in fetal and neonatal liver: implications for fatty acid requirements. Early Hum Dev 5: 7-14.
31. Clandinin M T, Chappell J E, Heim T, Swyer P R, Chance G W (1981) Fatty acid utilization in perinatal de novo synthesis of tissues. Early Hum Dev 5: 355-66.
32. Clandinin M T, Chappell J E, Leong S, Heim T, Swyer P R, Chance G W (1980) Intrauterine fatty acid accretion rates in human brain: implications for fatty acid requirements. Early Hum Dev 4: 121-9.
33. Clausen J (1984) Demential syndromes and the lipid metabolism. Acta Neurol Scand 70: 345-55.
34. Connor W E, Lowensohn R, Hatcher L (1996) Increased docosahexaenoic acid levels in human newborn infants by administration of sardines and fish oil during pregnancy. Lipids 31: S183-7.
35. Conquer J A, Tierney M C, Zecevic J, Bettger W J, Fisher R H (2000) Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 35: 1305-12.
36. Corrigan F M, Horrobin D F, Skinner E R, Besson J A, Cooper M B (1998) Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol 30: 197-207.
37. Crawford M A, Golfetto I, Ghebremeskel K, Min Y, Moodley T, Poston L, Phylactos A, Cunnane S, Schmidt W (2003) The potential role for arachidonic and docosahexaenoic acids in protection against some central nervous system injuries in preterm infants. Lipids 38: 303-15.
38. Crawford M A, Hassam A G, Williams G (1976) Essential fatty acids and fetal brain growth. Lancet 1: 452-3.
39. Cunnane S C, Francescutti V, Brenna J T, Crawford M A (2000) Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formulafed infants not consuming dietary docosahexaenoate. Lipids 35: 105-11.
40. Das U N (2000) Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot Essent Fatty Acids 63: 351-62.
41. Das U N (2001) Is obesity an inflammatory condition? Nutrition 17: 953-66.
42. Das U N, Fams (2003) Long-chain polyunsaturated fatty acids in the growth and development of the brain and memory. Nutrition 19: 62-5.
43. Davidson K (1983) Schizophrenia-like psychoses associated with organic cerebral disorders: a review. Psychiatr Dev 1: 1-34.
44. de Groot R H, Hornstra G, van Houwelingen A C, Roumen F (2004) Effect of alpha-linolenic acid supplementation during pregnancy on maternal and neonatal polyunsaturated fatty acid status and pregnancy outcome. Am J Clin Nutr 79: 251-60.
45. de la Presa Owens S, Innis S M (2000) Diverse, region-specific effects of addition of arachidonic and docosahexanoic acids to formula with low or adequate linoleic and alpha-linolenic acids on piglet brain monoaminergic neurotransmitters. Pediatr Res 48: 125-30.
46. de Urquiza A M, Liu S, Sjoberg M, Zetterstrom R H, Griffiths W, Sjovall J, Perlmann T (2000) Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290: 2140-4.
47. Delion S, Chalon S, Guilloteau D, Besnard J C, Durand G (1996) alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem 66: 1582-91.
48. Di Biase A, Salvati S (1997) Exogenous lipids in myelination and myelination. Kaohsiung J Med Sci 13: 19-29.
49. Diaz-Arguelles V (2001) Deficiencia de ácidos grasos esenciales en el feto y en el recién nacido pretérmino. Rev Cubana Pediatr 73: 43-50.
50. Edmond J, Higa T A, Korsak R A, Bergner E A, Lee W N (1998) Fatty acid transport and utilization for the developing brain. J Neurochem 70: 1227-34.
51. Emsley R, Myburgh C, Oosthuizen P, van Rensburg S J (2002) Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159: 1596-8.
52. Emsley R, Oosthuizen P, van Rensburg S J (2003) Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs 17: 1081-91.
53. Engelhart M J, Geerlings M I, Ruitenberg A, Van Swieten J C, Hofman A, Witteman J C, Breteler M M (2002) Diet and risk of dementia: Does fat matter?: The Rotterdam Study. Neurology 59: 1915-21.
54. Faldella G, Govoni M, Alessandroni R, Marchiani E, Salvioli G P, Biagi P L, Spano C (1996) Visual evoked potentials and dietary long chain polyunsaturated fatty acids in preterm infants. Arch Dis Child Fetal Neonatal Ed 75: F108-12.
55. Fenton W S (2000) Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 47: 8-21.
56. Fenton W S, Dickerson F, Boronow J, Hibbeln J R, Knable M (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158: 2071-4.
57. Fomon S, Fat, in NUTRITION OF FORMAL INFANTS.1st EDITION, e. CRAVEN L, Editor. 1993, MOSBY: St.Louis. p. 106-14.
58. Foote K D, MacKinnon M J, Innis S M (1991) Effect of early introduction of formula vs fat-free parenteral nutrition on essential fatty acid status of preterm infants. Am J Clin Nutr 54: 93-7.
59. Friedland R P (2002) Lipid metabolism, epidemiology, and the mechanisms of Alzheimer's disease. Ann N Y Acad Sci 977: 387-90.
60. Fukui K, Onodera K, Shinkai T, Suzuki S, Urano S (2001) Impairment of learning and memory in rats caused by oxidative stress and aging, and changes, in antioxidative defense systems. Ann N Y Acad Sci 928: 168-75.
61. Gamoh S, Hashimoto M, Hossain S, Masumura S (2001) Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol 28: 266-70.
62. Gamoh S, Hashimoto M, Sugioka K, Shahdat Hossain M, Hata N, Misawa Y, Masumura S (1999) Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 93: 237-41.
63. Gibson R A, Makrides M (2000) n-3 polyunsaturated fatty acid requirements of term infants. Am J Clin Nutr 71: 251S-5S.
64. Gibson R A, Neumann M A, Makrides M (1996) Effect of dietary docosahexaenoic acid on brain composition and neural function in term infants. Lipids 31: S177-81.
65. Glen A (1994) A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases. Schizophr Res 12: 53-61.
66. Grant W (1997) Dietary links to Alzheimer's disease. Alz Dis Rev 2: 42-55.
67. Green P, Glozman S, Weiner L, Yavin E (2001) Enhanced free radical scavenging and decreased lipid peroxidation in the rat fetal brain after treatment with ethyl docosahexaenoate. Biochim Biophys Acta 1532: 203-12.
68. Guan Z, Wang Y, Cairns N J, Lantos P L, Dallner G, Sindelar P J (1999) Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 58: 740-7.
69. Haag M (2003) Essential fatty acids and the brain. Can J Psychiatry 48: 195-203.
70. Hamano H, Nabekura J, Nishikawa M, Ogawa T (1996) Docosahexaenoic acid reduces GABA response in substantia nigra neuron of rat. J Neurophysiol 75: 1264-70.
71. Harris W S (2004) Fish oil supplementation: evidence for health benefits. Cleve Clin J Med 71: 208-10, 212, 215-8 passim.
72. Hashimoto M, Hossain S, Shimada T, Sugioka K, Yamasaki H, Fujii Y, Ishibashi Y, Oka J, Shido O (2002) Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 81: 1084-91.
73. Hendrickse W, Stammers J P, Hull D (1985) The transfer of free fatty acids across the human placenta. Br J Obstet Gynaecol 92: 945-52.
74. Hibbeln J R, Salem N, Jr. (1995) Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 62: 1-9.
75. Hoffman D R, Birch E E, Birch D G, Uauy R D (1993) Effects of supplementation with omega 3 long-chain polyunsaturated fatty acids on retinal and cortical development in premature infants. Am J Clin Nutr 57: 807S-812S.
76. Hogyes E, Nyakas C, Kiliaan A, Farkas T, Penke B, Luiten P G (2003) Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience 119: 999-1012.
77. Hollman C (1983) A trial of evening primrose oil in the treatment of chronic schizophrenia. J Orthomol Psychiatry 12: 302-304.
78. Horrobin D F (1994) The membrane hypothesis of schizophrenia. Schizophr Res 13: 195-207.
79. Horrobin D F (1996) Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids 55: 3-7.
80. Horrocks L A, Yeo Y K (1999) Health benefits of docosahexaenoic acid (DHA). Pharmacol Res 40: 211-25.
81. Igbavboa U, Hamilton J, Kim H Y, Sun G Y, Wood W G (2002) A new role for apolipoprotein E: modulating transport of polyunsaturated phospholipid molecular species in synaptic plasma membranes. J Neurochem 80: 255-61.
82. Ikemoto A, Kobayashi T, Watanabe S, Okuyama H (1997) Membrane fatty acid modifications of PC12 cells by arachidonate or docosahexaenoate affect neurite outgrowth but not norepinephrine release. Neurochem Res 22: 671-8.
83. Innis S M (1991) Essential fatty acids in growth and development. Prog Lipid Res 30: 39-103.
84. Innis S M (2000) The role of dietary n-6 and n-3 fatty acids in the developing brain. Dev Neurosci 22: 474-80.
85. Innis S M, Adamkin D H, Hall R T, Kalhan S C, Lair C, Lim M, Stevens D C, Twist P F, Diersen-Schade D A, Harris C L, Merkel K L, Hansen J W (2002) Docosahexaenoic acid and arachidonic acid enhance growth with no adverse effects in preterm infants fed formula. J Pediatr 140: 547-54.
86. Innis S M, Akrabawi S S, Diersen-Schade D A, Dobson M V, Guy D G (1997) Visual acuity and blood lipids in term infants fed human milk or formulae. Lipids 32: 63-72.
87. Jensen C L, Prager T C, Fraley J K, Chen H, Anderson R E, Heird W C (1997) Effect of dietary linoleic/alpha-linolenic acid ratio on growth and visual function of term infants. J Pediatr 131: 200-9.
88. Jones C R, Arai T, Rapoport S I (1997) Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. Neurochem Res 22: 663-70.
89. Jope R S (1982) Effects of phosphatidylcholine administration to rats on choline in blood and choline and acetylcholine in brain. J Pharmacol Exp Ther 220: 322-8.
90. Jorgensen M H, Hernell O, Hughes E, Michaelsen K F (2001) Is there a relation between docosahexaenoic acid concentration in mothers' milk and visual development in term infants? J Pediatr Gastroenterol Nutr 32: 293-6.
91. Joy C B, Mumby-Croft R, Joy L A (2003) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev CD001257.
92. Kalmijn S (2000) Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. J Nutr Health Aging 4: 202-7.
93. Kalmijn S, Feskens E J, Launer L J, Kromhout D (1997) Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 145: 33-41.
94. Kim D N, Eastman A, Baker J E, Mastrangelo A, Sethi S, Ross J S, Schmee J, Thomas W A (1995) Fish oil, atherogenesis, and thrombogenesis. Ann N Y Acad Sci 748: 474-80; DISCUSSION 480-1.
95. Kim H Y, Akbar M, Lau A, Edsall L (2000) Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine in antiapoptotic effect. J Biol Chem 275: 35215-23.
96. Kim H Y, Edsall L (1999) The role of docosahexaenoic acid (22:6n-3) in neuronal signaling. Lipids 34: S249-50.
97. Kodas E, Vancassel S, Lejeune B, Guilloteau D, Chalon S (2002) Reversibility of n-3 fatty acid deficiency-induced changes in dopaminergic neurotransmission in rats: critical role of developmental stage. J Lipid Res 43: 1209-19.
98. Kyle D J, Schaefer E, Patton G, Beiser A (1999) Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 34: S245.
99. Lamb L E, Simon J D (2004) A2E: a component of ocular lipofuscin. Photochem Photobiol 79: 127-36.
100. Laurin D, Verreault R, Lindsay J, Dewailly E, Holub B J (2003) Omega-3 fatty acids and risk of cognitive impairment and dementia. J Alzheimers Dis 5: 315-22.
101. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M (2000) Polyunsaturated fatty acids are potent neuroprotectors. Embo J 19: 1784-93.
102. Lengqvist J, De Urquiza A M, Bergman A C, Wilson T M, Sjovall J, Perlmann T, Griffiths W J (2004) Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand binding domain. Mol Cell Proteomics 8: 8.
103. Lim S, Suzuki H (2001) Changes in maze behavior of mice occur after sufficient accumulation of docosahexaenoic acid in brain. J Nutr 131: 319-24.
104. Lim S Y, Suzuki H (2000) Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice. J Nutr 130: 1629-32.
105. Lucas A. Long-chain polyunsaturated fatty acids, infant feeding, and cognitive development., in Developing Brain and Behaviour: The Role of Lipids in Infant Formula., e. Dobbing J, Editor. 1997, Academic Press: New York, NY. p. 3-40.
106. Lucas A, Stafford M, Morley R, Abbott R, Stephenson T, MacFadyen U, Elias-Jones A, Clements H (1999) Efficacy and safety of long-chain polyunsaturated fatty acid supplementation of infant-formula milk: a randomised trial. Lancet 354: 1948-54.
107. Maidment I (2000) Are fish oils an effective therapy in mental illness: an analysis of the data. Acta Psychiatr Scand 102: 3-11.
108. Makrides M, Neumann M, Simmer K, Pater J, Gibson R (1995) Are long-chain polyunsaturated fatty acids essential nutrients in infancy? Lancet 345: 1463-8.
109. Makrides M, Neumann M A, Jeffrey B, Lien E L, Gibson R A (2000) A randomized trial of different ratios of linoleic to alpha-linolenic acid in the diet of term infants: effects on visual function and growth. Am J Clin Nutr 71: 120-9.
110. Makrides M, Neumann M A, Simmer K, Gibson R A (2000) A critical appraisal of the role of dietary long-chain polyunsaturated fatty acids on neural indices of term infants: a randomized, controlled trial. Pediatrics 105: 32-8.
111. Malcolm C A, McCulloch D L, Montgomery C, Shepherd A, Weaver L T (2003) Maternal docosahexaenoic acid supplementation during pregnancy and visual evoked potential development in term infants: a double blind, prospective, randomised trial. Arch Dis Child Fetal Neonatal Ed 88: F383-90.
112. Markesbery WR, Carney J M (1999) Oxidative alterations in Alzheimer's disease. Brain Pathol 9: 133-46.
113. Martinez M (1992) Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr 120: S129-38.
114. Mayeux R (2003) Epidemiology of neurodegeneration. Annu Rev Neurosci 26: 81-104. Epub 2003 Jan 24.
115. McGahon B M, Martin D S, Horrobin D F, Lynch M A (1999) Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 94: 305-14.
116. Mellor J (1995) Schizophrenic symptoms and dietary intake of n-3 fatty acids (letter to the editor). Schizophr Res 18: 85-86.
117. Menadue J, The long chain polyunsaturated fatty acid status of pregnant and lactating women:effect of diet on the mother and infant. 1992, Flinders University of South Australia: Adelaide.
118. Meydani S N (1996) Effect of (n-3) polyunsaturated fatty acids on cytokine production and their biologic function. Nutrition 12:S8-14.
119. Minami M, Kimura S, Endo T, Hamaue N, Hirafuji M, Togashi H, Matsumoto M, Yoshioka M, Saito H, Watanabe S, Kobayashi T, Okuyama H (1997) Dietary docosahexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol Biochem Behav 58: 1123-9.
120. Moher D, Dulberg C S, Wells G A (1994) Statistical power, sample size, and their reporting in randomized controlled trials. Jama 272: 122-4.
121. Moore S A, Yoder E, Murphy S, Dutton G R, Spector A A (1991) Astrocytes, not neurons, produce docosahexaenoic acid (22:6 omega-3) and arachidonic acid (20:4 omega-6). J Neurochem 56: 518-24.
122. Moore S A, Yoder E, Spector A A (1990) Role of the blood-brain barrier in the formation of long-chain omega-3 and omega-6 fatty acids from essential fatty acid precursors. J Neurochem 55: 391-402.
123. Moriguchi T, Loewke J, Garrison M, Catalan J N, Salem N, Jr. (2001) Reversal of docosahexaenoic acid deficiency in the rat brain, retina, liver, and serum. J Lipid Res 42: 419-27.
124. Morris M C, Evans D A, Bienias J L, Tangney C C, Bennett D A, Wilson R S, Aggarwal N, Schneider J (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60: 940-6.
125. Morris R G, Garrud P, Rawlins J N, O'Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297: 681-3.
126. Moser H W, Raymond G V, Koehler W, Sokolowski P, Hanefeld F, Korenke G C, Green A, Loes D J, Hunneman D H, Jones R O, Lu S E, Uziel G, Giros M L, Roels F (2003) Evaluation of the preventive effect of glyceryl trioleate-trierucate ("Lorenzo's oil") therapy in X-linked adrenoleukodystrophy: results of two concurrent trials. Adv Exp Med Biol 544: 369-87.
127. Munoz D G. Feldman H (2000) Causes of Alzheimer's disease. Cmaj 162: 65-72.
128. Nasrallah H (1993) Neurodevelopmental pathogenesis of schizophrenia. Psychiatr Clin North Am 16: 269-80.
129. Neuringer M, The relationship of fatty acid comopsition to function in the retina and visual system., in Lipids, Learning and the Brain: Fats in Infants Formulas., e. Dobbing J, Editor. 1993, Ross Laboratories.: Columbus, OH. p. 807S-812S:.
130. Neuringer M, Anderson G J, Connor W E (1988) The essentiality of n-3 fatty acids for the development and function of the retina and brain. Annu Rev Nutr 8: 517-41.
131. Neuringer M, Connor W E, Lin D S, Barstad L, Luck S (1986) Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc Natl Acad Sci U S A 83: 4021-5.
132. Nishikawa M, Kimura S, Akaike N (1994) Facilitatory effect of docosahexaenoic acid on N-methyl-D-aspartate response in pyramidal neurones of rat cerebral cortex. J Physiol 475: 83-93.
133. Nitta A, Fukuta T, Hasegawa T, Nabeshima T (1997) Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn J Pharmacol 73: 51-7.
134. Nitta A, Itoh A, Hasegawa T, Nabeshima T (1994) beta-Amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 170: 63-6.
135. Nourooz-Zadeh J, Liu E H, Yhlen B, Anggard E E,Halliwell B (1999) F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem 72: 734-40.
136. O'Connor D L, Hall R, Adamkin D, Auestad N, Castillo M, Connor W E, Connor S L, Fitzgerald K, Groh-Wargo S, Hartmann E E, Jacobs J, Janowsky J, Lucas A, Margeson D, Mena P, Neuringer M, Nesin M, Singer L, Stephenson T, Szabo J, Zemon V (2001) Growth and development in preterm infants fed long-chain polyunsaturated fatty acids: a prospective, randomized controlled trial. Pediatrics 108: 359-71.
137. Okada M, Amamoto T, Tomonaga M, Kawachi A, Yazawa K, Mine K, Fujiwara M (1996) The chronic administration of docosahexaenoic acid reduces the spatial cognitive deficit following transient forebrain ischemia in rats. Neuroscience 71: 17-25.
138. Peet M (1996) Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 55: 71-75.
139. Peet M (1998) Depletion of omega-3 fatty acid levels in red blood cell membrane of depressive patients. Biol Psychiatry 43: 315-319.
140. Peet M (2001) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49: 243-51.
141. Peet M (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persisting schizophrenic symptoms. J Psychiatr Res 36: 7-18.
142. Penzo D, Tagliapietra C, Colonna R, Petronilli V, Bernardi P (2002) Effects of fatty acids on mitochondria: implications for cell death. Biochim Biophys Acta 1555: 160-5.
143. Prasad M R, Lovell M A, Yatin M, Dhillon H, Markesbery W R (1998) Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23: 81-8.
144. Puri B K (1998) Sustained remission of positive and negative symptoms of schizophrenia after treatment with eicosapentaenoic acid. Arch Gen Psychiatry 55: 188-189.
145. Rapoport S I (2003) In vivo approaches to quantifying and imaging brain arachidonic and docosahexaenoic acid metabolism. J Pediatr 143: S26-34.
146. Reich E E, Markesbery W R, Roberts L J, 2nd, Swift L L, Morrow J D, Montine T J (2001) Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 158: 293-7.
147. Reisbick S, Neuringer M, Gohl E, Wald R,Anderson G J (1997) Visual attention in infant monkeys: effects of dietary fatty acids and age. Dev Psychol 33: 387-95.
148. Roberts L J, 2nd, Montine T J, Markesbery W R, Tapper A R, Hardy P, Chemtob S, Dettbarn W D, Morrow J D (1998) Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 273: 13605-12.
149. Rogan W J, Gladen B C (1993) Breast-feeding and cognitive development. Early Hum Dev 31: 181-93.
150. Roher A E, Weiss N, Kokjohn T A, Kuo Y M, Kalback W, Anthony J, Watson D, Luehrs D C, Sue L, Walker D, Emmerling M, Goux W, Beach T (2002) Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 41: 11080-90.
151. Rudin D (1981) The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome:substrate pellagra. Biol Psychiatry 16: 837-850.
152. Ruyle M, Connor W E, Anderson G J, Lowensohn R I (1990) Placental transfer of essential fatty acids in humans: venous-arterial difference for docosahexaenoic acid in fetal umbilical erythrocytes. Proc Natl Acad Sci U S A 87: 7902-6.
153. Salvati S, Attorri L, Avellino C, Di Biase A, Sanchez M (2000) Diet, lipids and brain development. Dev Neurosci 22: 481-7.
154. Salvati S, Attorri L, Avellino C, Di Biase A, Sanchez M (2002) Dietary prenatal lipids affect myelin gene expression in postnatal undernourished rats. Nutr Neurosci 5: 243-50.
155. Salvati S, Sanchez M, Campeggi L M, Suchanek G, Breitschop H, Lassmann H (1996) Accelerated myelinogenesis by dietary lipids in rat brain. J Neurochem 67: 1744-50.
156. Saste M D, Carver J D, Stockard J E, Benford V J, Chen L T, Phelps C P (1998) Maternal diet fatty acid composition affects neurodevelopment in rat pups. J Nutr 128: 740-3.
157. Scott D T, Janowsky J S, Carroll R E, Taylor J A, Auestad N, Montalto M B (1998) Formula supplementation with long-chain polyunsaturated fatty acids: are there developmental benefits? Pediatrics 102: E59.
158. Selten J P (1997) Second-trimester exposure to maternal stress is a possible factor for psychotic illness in the child. Schizophr Res 24: 258 (abstract).
159. Sessler A M, Ntambi J M (1998) Polyunsaturated fatty acid regulation of gene expression. J Nutr 128: 923-6.
160. Shah S. Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia, in 9th Schizophrenia Winter Workshop. 1998. Davos.
161. Shirai N, Suzuki H (2004) Effect of dietary docosahexaenoic acid and catechins on maze behavior in mice. Ann Nutr Metab 48: 51-8. Epub 2003 Nov 28.
162. Simmer K (2001) Longchain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev CD000376.
163. Simmer K, Patole S (2004) Longchain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst Rev CD000375.
164. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti C G, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 95: 6460-4.
165. Sinclair H M (1956) Deficiency of essential fatty acids and atherosclerosis. Lancet 1: 381-3.
166. Smuts C M, Borod E, Peeples J M, Carlson S E (2003) High-DHA eggs: feasibility as a means to enhance circulating DHA in mother and infant. Lipids 38: 407-14.
167. Soderberg M, Edlund C, Kristensson K, Dallner G (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26: 421-5.
168. Sprecher H, Chen Q (1999) Polyunsaturated fatty acid biosynthesis: a microsomal-peroxisomal process. Prostaglandins Leukot Essent Fatty Acids 60: 317-21.
169. Strokin M, Sergeeva M,Reiser G (2003) Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca2+. Br J Pharmacol 139: 1014-22.
170. Su H M, Bernardo L, Mirmiran M, Ma X H, Corso T N, Nathanielsz P W, Brenna J T (1999) Bioequivalence of dietary alpha-linolenic and docosahexaenoic acids as sources of docosahexaenoate accretion in brain and associated organs of neonatal baboons. Pediatr Res 45: 87-93.
171. Tolley E A, Carlson S E (2000) Considerations of statistical power in infant studies of visual acuity development and docosahexaenoic acid status. Am J Clin Nutr 71: 1-2.
172. Tully A M, Roche H M, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney M J (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 89: 483-9.
173. Turner N, Else PL, Hulbert A J (2003) Docosahexaenoic acid (DHA) content of membranes determines molecular activity of the sodium pump: implications for disease states and metabolism. Naturwissenschaften 90: 521-3. Epub 2003 Oct 10.
174. Uauy R, Birch E, Birch D, Peirano P (1992) Visual and brain function measurements in studies of n-3 fatty acid requirements of infants. J Pediatr 120: S168-80.
175. Vaddadi K (1979) Penicillin and essential fatty acid supplementation in schizophrenia. Prostaglandins Med 2: 77-80.
176. Vaddadi K (1986) A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology 88: 362-367.
177. Vaddadi K (1989) A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatr Res 27: 313-323.
178. Valenzuela A, Von Bernhardi R, Valenzuela V Ramirez G, Alarcon R, Sanhueza J, Nieto S (2004) Supplementation of female rats with alpha-linolenic acid or docosahexaenoic acid leads to the same omega-6/omega-3 LC-PUFA accretion in mother tissues and in fetal and newborn brains. Ann Nutr Metab 48: 28-35. Epub 2003 Nov 20.
179. van Os J (1997) Developmental precursors of affective illness in a general population birth cohort. Arch Gen Psychiatry 625-631.
180. Vanderhoof J, Gross S, Hegyi T, Clandinin T, Porcelli P, DeCristofaro J, Rhodes T, Tsang R, Shattuck K, Cowett R, Adamkin D, McCarton C, Heird W, Hook-Morris B, Pereira G, Chan G, Van Aerde J, Boyle F, Pramuk K, Euler A, Lien E L (1999) Evaluation of a long-chain polyunsaturated fatty acid supplemented formula on growth, tolerance, and plasma lipids in preterm infants up to 48 weeks postconceptional age. J Pediatr Gastroenterol Nutr 29: 318-26.
181. Voigt R G, Jensen C L, Fraley J K, Rozelle J C, Brown F R, 3rd, Heird W C (2002) Relationship between omega3 long-chain polyunsaturated fatty acid status during early infancy and neurodevelopmental status at 1 year of age. J Hum Nutr Diet 15: 111-20.
182. Vreugdenhil M, Bruehl C, Voskuyl R A, Kang J X, Leaf A,Wadman W J (1996) Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc Natl Acad Sci U S A 93: 12559-63.
183. Willson T M, Brown P J, Sternbach D D, Henke B R (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43: 527-50:
184. Wirths O, Multhaup G, Czech C, Feldmann N, Blanchard V, Tremp G, Beyreuther K, Pradier L, Bayer T A (2002) Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol 12: 275-86.
185. Wolkin A (1986) Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry 143: 912-914.
186. Yehuda S, Rabinovitz S, Mostofsky D I (1999) Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res 56: 565-70.
187. Yoshida S, Sato A, Okuyama H (1998) Pathophysiological effects of dietary essential fatty acid balance on neural systems. Jpn J Pharmacol 77: 11-22.
188. Yoshida S, Yasuda A, Kawazato H, Sakai K, Shimada T, Takeshita M, Yuasa S, Kobayashi T, Watanabe S, Okuyama H (1997) Synaptic vesicle ultrastructural changes in the rat hippocampus induced by a combination of alpha-linolenate deficiency and a learning task. J Neurochem 68: 1261-8.
189. Youdim K A, Martin A, Joseph J A (2000) Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 18: 383-99.
190. Young C, Gean P W, Chiou L C, Shen Y Z (2000) Docosahexaenoic acid inhibits synaptic transmission and epileptiform activity in the rat hippocampus. Synapse 37: 90-4.
191. Yu N, Martin J L, Stella N, Magistretti P J (1993) Arachidonic acid stimulates glucose uptake in cerebral cortical astrocytes. Proc Natl Acad Sci U S A 90: 4042-6.